|
Advertisement
|
|
Home > BioSpectrum TOP 20
| Rank 21-50 Companies |
|
|
| Tuesday, June 09, 2009 |
Rank 21-50 Companies

Hester Biosciences Limited is a veterinary vaccines manufacturing
company, which has ISO 9001-2000 and GMP certifications. The product
range includes 11 types of live and 28 types of inactivated poultry
vaccines. Propagation of micro-organisms for manufacturing of the
vaccines is done through tissue culture, through specific pathogen free
embryos and through fermentation processes. Having achieved a turnover
of Rs 32.60 crore in 2007-08, Hester claims to have the second largest
market share for poultry vaccines in India. Hester
imports one vaccine from the US. It also exports some of its
vaccines to three countries and registration are pending in over 10
countries. Besides marketing its own vaccines, Hester represents other
companies like Merial USA for poultry vaccines; Biopharm, Czech
Republic, for poultry vaccines; Synbiotics, USA, for animal diagnostic
kits for the Indian market.

Cadila Pharmaceuticals (CPL) is a key research-based, tech-savvy
pharmaceutical company focusing on areas like formulations, new drug
discovery, active pharmaceutical ingredients, analytical research,
phytochemistry, biotechnology, plant tissue culture, biosynthesis,
genetic engineering, vaccines and immunoglobulins. Over the last few
years, CPL has established a strong R&D base in biotechnology
and developed working relations with key R&D institutes in the
country. CPL has its own research facility at Indian Institute of
Science (IISc) Bangalore. About 20 products including
conventional and recombinant vaccines, anti-cancer biotherapeutics,
diagnostics using recombinant antigens and natural thrombolites with
high market potential are in its biotechnology basket. Cadila has
developed Immuvac, a potent immunomodulator for the first time in the
world. Sodium Hyaluronate, is another biotech product developed on the
basis of technology obtained from Center for Biochemical Technology,
Delhi.

JK Agri Genetics Ltd (JKAL) was established in 1989 with its
headquarters at Hyderabad. The biotechnology division of the company is
engaged in R&D, production, processing and marketing of hybrid
seeds of sorghum, pearl millet, maize, cotton, rice, sunflower, tomato,
okra and hot pepper.
JKAL has invested extensively in biotechnology programs and has
collaborations with several national and international research
institutions and agricultural universities to harness biotechnology for
crop improvement. The company has developed a range of superior hybrids
with Bt gene and other novel genes that fulfills farmers’
aspirations. A team of 15 scientists are currently working on the
application of DNA markers such as RFLP, AFLP, SSR and ISSR,
agrobacterium and biolistic mediated transformation technology in
various crops using novel genes and application of in-vitro culture.

Maps India is a producer and exporter of industrial enzymes. With over
150 employees, sophisticated production plant and a dedicated
R&D center, Maps India has become a key player in enzymes and
microorganisms. A team of 30 scientists is involved in R&D
activities at Maps India. Maps produces a broad range of enzymes and
microorganisms that include amylases, proteases, cellulases, xylanase,
glucoamylase, pectinase, catalase and phytase, which are used for
industrial purposes. With a complex product portfolio of over 60
products, a sales network that covers 20 countries and products for
more than 10 different industries, Maps provides biotech solutions to
improve industrial performance and quality. Maps is investing Rs 10
crore in Gujarat to expand its expansion.

Suven Life Sciences is a collaborative research partner (CRP) in drug
discovery for global pharma companies since 2006. The company is also
focusing on contract research and manufacturing services (CRAMS) since
1995 and drug discovery and development support services (DDDSS) since
2005. Suven is engaged in discovering new chemical entities in central
nervous system (CNS) therapeutic areas including Alzheimer’s,
cognitive impairment, dementia, depression, Parkinson’s
disease and obesity which are at various phases of preclinical and
clinical development. The company has recently undergone US FDA
inspection at their intermediate/active pharmaceutical ingredient (API)
facility in Suryapet, Andhra Pradesh. The company’s revenues
from DDDSS stood at Rs 21.03 crore.

Varda Biotech is a technology and knowledge-based enterprise, offering
integrated services to biotechnology and pharmaceutical companies. It
engages in high-end collaboration for the products and services that
enhance the capability and productivity performances of its customers
and business associates. Varda offers an ultra pure and highly
thermostable recombinant Taq DNA Polymerase that has been isolated from
recombinant E.coli. Varda provides custom service for clients requiring
custom made peptides for research use, which are of either linear
sequence or modified ones. Varda has received the ISO 9001:2000
certificate. It has the technical expertise to produce and deliver
quality antibodies for life science research community. The company has
launched educational biotechnology kits under the brand name
Bio-Knowledge Kit and has alliance with global players for product
association and representation in India too.

Celestial Labs has been supporting pharma, bio-pharma and biotech
manufacturing with customized IT solutions and contract research. The
company is also involved in R&D, commercial production and
marketing of enzymes and nutraceuticals. Celestial Labs is setting up a
biotechnology facility at Genome Valley in Hyderabad to manufacture its
own drug molecules, industrial enzymes and contract research
activities. The business plan of Celestial Labs is essentially based on
the production and supply of the biotechnological products which have
very significant industrial implications, especially in both pharma and
biopharmaceutical sectors. Celestial Labs has been engaged in
production of custom peptides for last five years. The acquisition of
Bioconcept, an advanced facility for automated equipment, has
establishing itself as a reliable source of contract research services
on custom peptide synthesis.

Shreya Group started its operation in Moscow, Russia, where Shreya
Corporation, the parent company, was established in 1995. Once a
one-man trading company, Shreya is a marketing and distribution company
in Russia. Shreya Group has interests in both pharmaceutical and
biopharmaceutical products in key therapeutic segments. Shreya Life
Sciences, the Indian arm of Shreya Group, started its operations in
India in 2001 by acquiring Rallis India Ltd, a TATA Group company. In
2003, Shreya acquired the domestic pharma business of Plethico
Pharmaceuticals Ltd, with a view to achieve a full-fledged national
presence. Some of the products in human insulin introduced by
Shreya in India include, Recosulin-M30 40 I.U, Recosulin-M30
100 I.U, Recosulin-M50 100 I.U,Recosulin-M50 40 I.U, Recosulin-N 100
I.U, Recosulin-N 40 I.U, Recosulin-R 100 I.U and Recosulin-R
40 I.U.

Zytex (India) Pvt Ltd is engaged in marketing of a broad range of
biotechnological products. Zytex believes that the product research
should be backed by application development. Hence it set up an
application lab in 1997 to support the customers and also to develop
products from the bench scale to the customer rapidly. Based on
research conducted at its center, Zytex is now in the process of
setting up a new production facility for a range of therapeutic enzymes
and proteins. Its research laboratory is well equipped and manned with
qualified professionals. Zytex has also set up an ISO 9001:2000
certified manufacturing unit. Zytex markets a broad range of
biotechnological products that are unique and are specifically demanded
by customers. Zytex has strong distribution network in India and also
in Asia/South East Asia.

Bhat Bio-tech India specializes in the design development, manufacture
and marketing of diagnostic devices for tests like pregnancy, HIV,
hepatitis, malaria, dengue, chikungunya, syphlis, TB, cardiac markers,
dry chemistry, biochemistry, hematology, immunology and ELISA test used
in the analysis of body fluids in human. The company has registered
revenue of Rs 12.10 crore in FY09. Bhat Bio-tech has recently
got the technology transfer from Defence Research & Development
Establishment (DRDE) for manufacturing rapid test for toxin (ricin).
This is an immunochromatography-based test which will detect the ricin
as low as 50ng/ml in the sample. The company has launched the rapid
test for the detection of IgM antibodies for chikungunya virus in human
serum or plasma and also launched the AIDSCAN HIV-1/2 Trispot
Test based on immunoconcentration principle and uses human
serum or plasma and identifies HIV-1 and HIV-2 separately.

Multiplex Biotech has clocked revenues of Rs 12 crore in fiscal year
2008-09 as against Rs 15 crore in 2007-08. The increased revenue in
2007-08 was a result of a bulk order placement from Andaman and Nicobar
which contributed about Rs 5 crore in the last fiscal. Multiplex is
promoted by Dr GP Shetty, an entrepreneur having vast experience in the
field of manufacturing and marketing of agricultural products such as
multimicronutrient fertilizers, pesticides, seeds, insecticides etc.
The company has an unit at Nelamangala which is manufacturing wide
range of agro-based biotech products which are used for the growth,
development and to get more yields in field crops, fruit crops,
plantation crops, horticultural crops etc.

ABL Biotechnologies Limited (ABL), based in Chennai, is a pioneer in
harnessing the biodiversity of the Indian marine environment. ABL has
been working on identification and commercial extraction of
bio-chemicals, predominantly from microbes, that have far reaching
applications as nutritional, cosmetic, pharmaceutical and industrial
intermediates. The microbial metabolites Laboratory at Chennai works on
evaluating new sources of biochemicals from marine organisms. ABL has
been conducting research on polysaccharides, essential fatty acids,
natural pigments, tracers and tags with considerable success. Present
focus includes work on pharmaceuticals like anti-bacterials and
anti-virals, enzymes, bio-molecular materials, bio-monitors and
diagnostics, bio-pesticides, bioremediation and aquaculture.
ABL’s efforts are focused on the enormous potential of Indian
biodiversity for the production of new tools to both fight as well as
prevent disease.

Metahelix Life Sciences is an agricultural biotechnology company
focused on developing traits and technologies for crop protection and
improved productivity. Metahelix markets hybrid seeds by its
wholly-owned subsidiary seeds business, Dhaanya Seeds. Metahelix has
developed two versions of Bt cotton and a Bt rice hybrid that controls
rice yellow stem borer (YSB) using the Bt based Cry1Ac gene. The
company’s biotechnology capability includes all the aspects
of gene mining, development, molecular biology, crop transformation,
phenotyping, assaying and trait development. The company’s
research initiatives include developing hybrid seeds of rice, maize,
cotton (Bt), millet, sunflower, sorghum, tomato, okra, hot pepper,
melons. and research and development of biotech traits like insect
protection, virus protection and fungal disease protection. The company
currently employs 230 people and plans to hire another 40 by next year.

Zenotech Laboratories is a Hyderabad-based biopharmaceutical company
which develops new biological entities in the areas of cancer and
neurology. The company has initiated target identification and
validation programs using gene and protein based technologies. This
brings together proprietary technologies in the identification of cell
surface proteins and receptors as candidate drug targets. Zenotech also
develops and manufactures generic biopharmaceuticals and also offers
comprehensive services for generating and characterizing recombinant
proteins. The company provides a full range of services from cloning a
gene, expression in microbial or mammalian systems, process development
and generation of milligram to gram quantities of pure recombinant
proteins. The company also offers functional, validated assays in both
cell-based and cell-free formats for use in drug discovery.

Excel Industries Ltd primarily manufactures chemicals for industrial
and agricultural needs. The business divisions of Excel include agri,
chemical, and environment and biotech. The environment and biotech
division has developed biodynamic products and processes for tackling
environment and biotech problems. Excel’s activities include
sanitization, bioconversion, bioremediation and bioaugmentation. The
environment and biotech division has two product categories namely
agricultural biotech products and environment biotech products. The
agricultural biotech products make extensive use of naturally occurring
microbes such as bacteria and fungi. The products are broadly
classified under the categories of soil enrichers and biopesticides,
and the division makes extensive use of naturally occurring microbes
that helps in the aerobic decomposition of organic matter in its
various forms such as agricultural and food waste, animal waste that
includes fats and proteins.
Page(s) 1 2 |
|
|
| |
|
|
|
|